Shares of Targacept (TRGT) slide 26% after the firm releases top-line results from its second...

|By:, SA News Editor

Shares of Targacept (TRGT) slide 26% after the firm releases top-line results from its second Phase 3 study of its antidepressant therapy TC-5214 that fails to meet its primary goal.